Fundación Cardiovascular de Colombia
Welcome,         Profile    Billing    Logout  
 6 Trials 
29 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Martinez, Carlos E
NCT05686044: A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

Completed
2/3
351
US
Buntanetap/Posiphen, Posiphen Tartrate, Placebo
Annovis Bio Inc.
Alzheimer Disease
02/24
02/24
NCT05272865: Pharmacokinetic and Pharmacodynamic Evaluation of Formulations of Δ9-THC

Not yet recruiting
1/2
334
RoW
Pharmacokinetic and pharmacodynamic profile of THC oral formulations with Dronabinol as comparator, Administration of different Cannabis oral formulations with THC as compared with Active comparator (DRONABINOL)
LaSanta S A S
Nausea Post Chemotherapy, Vomiting, Cancer Pain, Cancer Related Pain, Neoplasms
02/24
10/24
NCT03011554: Telescope Exchange Study

Recruiting
N/A
75
US
Implantable Miniature Telescope (IMT)
VisionCare, Inc.
Age-related Macular Degeneration
12/19
12/22
TRIDENT, NCT02986984: Transformative Research in Diabetic Nephropathy

Recruiting
N/A
400
US
There is no intervention, There are no interventions
University of Pennsylvania, MOUNT SINAI HOSPITAL, University of North Carolina, Northwestern University, University of New Mexico, Stanford University, The University of Texas Health Science Center at San Antonio, Ohio State University, Yale University, Albert Einstein College of Medicine, Oregon Health and Science University, Lehigh Valley Health Network, University of Arkansas, University of Southern California, University of Virginia, Regeneron Pharmaceuticals, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Juvenile Diabetes Research Foundation, Novo Nordisk A/S
Diabetic Nephropathies, Diabetic Glomerulosclerosis
06/25
06/25
CONCERTO, NCT05438732: Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD

Recruiting
N/A
125
US
smaller incision, new generation implantable miniature telescope (SING-IMT)
VisionCare, Inc., ORA, Inc.
Age-Related Macular Degeneration, Geographic Atrophy
12/25
12/25
NCT05569005: Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.

Terminated
N/A
715
Europe, Japan, US, RoW
THS use, Tobacco Heating System 3.0, Cigarette, Smoking Abstinence
Philip Morris Products S.A.
COPD, Smoking, Tobacco Use
09/24
09/24
NCT05204888: MyAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

Recruiting
N/A
642
Canada, US
myAirvo3, Pulse oximeter
Temple University, Fisher and Paykel Healthcare
COPD
01/27
03/27
Sarmiento, Alba L Ramirez
NCT05496049: Efficacy of Triburter on Respiratory Muscle Function in Patients After CABG in Cardiac Rehabilitation Phase II

Completed
N/A
30
RoW
Triburter, Triburter device, Incentive spirometry
Fundación Cardiovascular de Colombia
Thoracic Surgery, Postoperative Period, Weakness, Muscle
12/23
12/23
Levi, Mauricio A Orozo
NCT05496049: Efficacy of Triburter on Respiratory Muscle Function in Patients After CABG in Cardiac Rehabilitation Phase II

Completed
N/A
30
RoW
Triburter, Triburter device, Incentive spirometry
Fundación Cardiovascular de Colombia
Thoracic Surgery, Postoperative Period, Weakness, Muscle
12/23
12/23
Chertkoff, Alejandro
TRANSCEND-T2D-2, NCT06260722: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor

Active, not recruiting
3
1250
Canada, US, RoW
Retatrutide, LY3437943, Semaglutide
Eli Lilly and Company
Diabetes Mellitus, Type 2
08/26
01/27
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
QWINT-1, NCT05662332: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
795
US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, T2D
07/24
07/24
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Active, not recruiting
3
1500
Europe, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Type 2 Diabetes
08/25
08/25
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
Costanzo, Pablo
QWINT-4, NCT05462756 / 2021-005878-25: A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

Completed
3
730
Europe, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Lispro (U100), Humalog, Insulin Glargine (U100), Basaglar
Eli Lilly and Company, Eli Lilly and Company
Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
02/24
02/24
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

Completed
3
692
Europe, Japan, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec
Eli Lilly and Company
Type 1 Diabetes, Diabetes
05/24
05/24
ATTAIN-OSA, NCT06649045: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Recruiting
3
600
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
OSA, Overweight or Obesity
11/26
01/27
TRIUMPH-5, NCT06662383: A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

Active, not recruiting
3
800
Europe, US, RoW
Retatrutide, LY3437943, Tirzepatide, LY3298176
Eli Lilly and Company
Obesity
12/26
12/26
SURMOUNT-5, NCT05822830: A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

Completed
3
751
US
Tirzepatide, LY3298176, Semaglutide
Eli Lilly and Company
Obesity, Overweight
11/24
11/24
SURPASS-T1D-1, NCT06914895: A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

Recruiting
3
905
Europe, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Type 1 Diabetes, Obesity, Overweight
05/27
05/27
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
1576
Japan, US, RoW
Orforglipron, LY3502970, Semaglutide
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
TRIUMPH-3, NCT05882045: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Active, not recruiting
3
1800
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Cardiovascular Diseases
01/26
02/26
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Active, not recruiting
3
1000
Europe, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
05/26
05/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT06143956: A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Recruiting
2
1040
US, RoW
LY3305677, LY3841136, Tirzepatide, Placebo, LY3549492
Eli Lilly and Company
Obesity, Overweight
06/26
09/26
NCT06603571: A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Recruiting
2
350
US, RoW
LY3841136, Tirzepatide, Placebo
Eli Lilly and Company
Obesity, Overweight
06/26
08/26
NCT06037252: A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

Recruiting
2
350
US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Type 2 Diabetes, Obesity
01/26
10/26
NCT06901349: A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

Not yet recruiting
2
180
Canada, Japan, US, RoW
Bimagrumab, LY3985863, Tirzepatide, LY3298176, Bimagrumab Placebo, Tirzepatide Placebo
Eli Lilly and Company
Obesity, Overweight
10/26
01/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Martinez, Carlos E
NCT05686044: A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

Completed
2/3
351
US
Buntanetap/Posiphen, Posiphen Tartrate, Placebo
Annovis Bio Inc.
Alzheimer Disease
02/24
02/24
NCT05272865: Pharmacokinetic and Pharmacodynamic Evaluation of Formulations of Δ9-THC

Not yet recruiting
1/2
334
RoW
Pharmacokinetic and pharmacodynamic profile of THC oral formulations with Dronabinol as comparator, Administration of different Cannabis oral formulations with THC as compared with Active comparator (DRONABINOL)
LaSanta S A S
Nausea Post Chemotherapy, Vomiting, Cancer Pain, Cancer Related Pain, Neoplasms
02/24
10/24
NCT03011554: Telescope Exchange Study

Recruiting
N/A
75
US
Implantable Miniature Telescope (IMT)
VisionCare, Inc.
Age-related Macular Degeneration
12/19
12/22
TRIDENT, NCT02986984: Transformative Research in Diabetic Nephropathy

Recruiting
N/A
400
US
There is no intervention, There are no interventions
University of Pennsylvania, MOUNT SINAI HOSPITAL, University of North Carolina, Northwestern University, University of New Mexico, Stanford University, The University of Texas Health Science Center at San Antonio, Ohio State University, Yale University, Albert Einstein College of Medicine, Oregon Health and Science University, Lehigh Valley Health Network, University of Arkansas, University of Southern California, University of Virginia, Regeneron Pharmaceuticals, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Juvenile Diabetes Research Foundation, Novo Nordisk A/S
Diabetic Nephropathies, Diabetic Glomerulosclerosis
06/25
06/25
CONCERTO, NCT05438732: Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD

Recruiting
N/A
125
US
smaller incision, new generation implantable miniature telescope (SING-IMT)
VisionCare, Inc., ORA, Inc.
Age-Related Macular Degeneration, Geographic Atrophy
12/25
12/25
NCT05569005: Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.

Terminated
N/A
715
Europe, Japan, US, RoW
THS use, Tobacco Heating System 3.0, Cigarette, Smoking Abstinence
Philip Morris Products S.A.
COPD, Smoking, Tobacco Use
09/24
09/24
NCT05204888: MyAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

Recruiting
N/A
642
Canada, US
myAirvo3, Pulse oximeter
Temple University, Fisher and Paykel Healthcare
COPD
01/27
03/27
Sarmiento, Alba L Ramirez
NCT05496049: Efficacy of Triburter on Respiratory Muscle Function in Patients After CABG in Cardiac Rehabilitation Phase II

Completed
N/A
30
RoW
Triburter, Triburter device, Incentive spirometry
Fundación Cardiovascular de Colombia
Thoracic Surgery, Postoperative Period, Weakness, Muscle
12/23
12/23
Levi, Mauricio A Orozo
NCT05496049: Efficacy of Triburter on Respiratory Muscle Function in Patients After CABG in Cardiac Rehabilitation Phase II

Completed
N/A
30
RoW
Triburter, Triburter device, Incentive spirometry
Fundación Cardiovascular de Colombia
Thoracic Surgery, Postoperative Period, Weakness, Muscle
12/23
12/23
Chertkoff, Alejandro
TRANSCEND-T2D-2, NCT06260722: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor

Active, not recruiting
3
1250
Canada, US, RoW
Retatrutide, LY3437943, Semaglutide
Eli Lilly and Company
Diabetes Mellitus, Type 2
08/26
01/27
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
QWINT-1, NCT05662332: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
795
US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, T2D
07/24
07/24
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Active, not recruiting
3
1500
Europe, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Type 2 Diabetes
08/25
08/25
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
Costanzo, Pablo
QWINT-4, NCT05462756 / 2021-005878-25: A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

Completed
3
730
Europe, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Lispro (U100), Humalog, Insulin Glargine (U100), Basaglar
Eli Lilly and Company, Eli Lilly and Company
Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
02/24
02/24
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

Completed
3
692
Europe, Japan, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec
Eli Lilly and Company
Type 1 Diabetes, Diabetes
05/24
05/24
ATTAIN-OSA, NCT06649045: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Recruiting
3
600
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
OSA, Overweight or Obesity
11/26
01/27
TRIUMPH-5, NCT06662383: A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

Active, not recruiting
3
800
Europe, US, RoW
Retatrutide, LY3437943, Tirzepatide, LY3298176
Eli Lilly and Company
Obesity
12/26
12/26
SURMOUNT-5, NCT05822830: A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

Completed
3
751
US
Tirzepatide, LY3298176, Semaglutide
Eli Lilly and Company
Obesity, Overweight
11/24
11/24
SURPASS-T1D-1, NCT06914895: A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

Recruiting
3
905
Europe, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Type 1 Diabetes, Obesity, Overweight
05/27
05/27
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
1576
Japan, US, RoW
Orforglipron, LY3502970, Semaglutide
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
TRIUMPH-3, NCT05882045: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Active, not recruiting
3
1800
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Cardiovascular Diseases
01/26
02/26
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Active, not recruiting
3
1000
Europe, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
05/26
05/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT06143956: A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Recruiting
2
1040
US, RoW
LY3305677, LY3841136, Tirzepatide, Placebo, LY3549492
Eli Lilly and Company
Obesity, Overweight
06/26
09/26
NCT06603571: A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Recruiting
2
350
US, RoW
LY3841136, Tirzepatide, Placebo
Eli Lilly and Company
Obesity, Overweight
06/26
08/26
NCT06037252: A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

Recruiting
2
350
US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Type 2 Diabetes, Obesity
01/26
10/26
NCT06901349: A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

Not yet recruiting
2
180
Canada, Japan, US, RoW
Bimagrumab, LY3985863, Tirzepatide, LY3298176, Bimagrumab Placebo, Tirzepatide Placebo
Eli Lilly and Company
Obesity, Overweight
10/26
01/27

Download Options